Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977119 · ClinicalTrials.gov registry record
Investigation of Genetic Determinants of Capecitabine Toxicity
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 240
- Enrollment target
NCT00977119 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 240 participants.
The verdict
NCT00977119 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 240 participants
- Enrollment target
Study Summary
The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia). Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, the frequency of polymorphisms and differences in drug metabolism.
Interventions
- OTHER Side-effect questionnaires
- OTHER research blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2009-11-23 |
| Est. Completion | 2021-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00977119
The ClinicalTrials.gov registry entry for NCT00977119 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Side-effect questionnaires is the first listed.
NCT00977119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00977119 about?
NCT00977119 is a clinical study titled "Investigation of Genetic Determinants of Capecitabine Toxicity". The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia). Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, ...
What is the current status of trial NCT00977119?
This trial is currently completed. The enrollment target is 240 participants. The study started on 2009-11-23. Estimated completion is 2021-06-21.
What interventions are being tested in trial NCT00977119?
The interventions under investigation include: Side-effect questionnaires (OTHER), research blood samples (OTHER).
Who is sponsoring clinical trial NCT00977119?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.